- Home
- IMUX vs LEE Comparison
IMUX vs LEE Comparison
Compare IMUX & LEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- LEE
- Stock Information
- Founded
- IMUX 2016
- LEE 1890
- Country
- IMUX United States
- LEE United States
- Employees
- IMUX N/A
- LEE N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- LEE Newspapers/Magazines
- Sector
- IMUX Health Care
- LEE Consumer Discretionary
- Exchange
- IMUX Nasdaq
- LEE Nasdaq
- Market Cap
- IMUX 86.3M
- LEE 90.6M
- IPO Year
- IMUX N/A
- LEE N/A
- Fundamental
- Price
- IMUX $0.95
- LEE $11.99
- Analyst Decision
- IMUX Strong Buy
- LEE
- Analyst Count
- IMUX 6
- LEE 0
- Target Price
- IMUX $12.67
- LEE N/A
- AVG Volume (30 Days)
- IMUX 1.0M
- LEE 30.5K
- Earning Date
- IMUX 02-20-2025
- LEE 02-06-2025
- Dividend Yield
- IMUX N/A
- LEE N/A
- EPS Growth
- IMUX N/A
- LEE N/A
- EPS
- IMUX N/A
- LEE N/A
- Revenue
- IMUX N/A
- LEE $600,264,000.00
- Revenue This Year
- IMUX N/A
- LEE N/A
- Revenue Next Year
- IMUX N/A
- LEE N/A
- P/E Ratio
- IMUX N/A
- LEE N/A
- Revenue Growth
- IMUX N/A
- LEE N/A
- 52 Week Low
- IMUX $0.92
- LEE $7.57
- 52 Week High
- IMUX $2.11
- LEE $19.63
- Technical
- Relative Strength Index (RSI)
- IMUX 44.34
- LEE 36.69
- Support Level
- IMUX $0.94
- LEE $11.87
- Resistance Level
- IMUX $1.02
- LEE $13.69
- Average True Range (ATR)
- IMUX 0.06
- LEE 0.92
- MACD
- IMUX 0.00
- LEE 0.01
- Stochastic Oscillator
- IMUX 44.96
- LEE 19.18
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About LEE Lee Enterprises Incorporated
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.